EBRT and HDR Brachytherapy for Unfavorable-intermediate High and Very High-risk Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Jan 1, 2027
  • participants needed
    60
  • sponsor
    University of Virginia
Send
Updated on 16 February 2024
See if I qualify
cancer
adenocarcinoma
prostate adenocarcinoma
androgens
pelvic mri
brachytherapy
digital rectal examination
external beam radiation therapy
digital rectal exam
antiandrogen therapy
adenocarcinoma of prostate
androgen suppression
prostate cancer

Summary

This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy (EBRT) treatments lead to less side effects. This study is also looking at patient outcomes, quality of life, and overall survival for patients receiving this treatment.

Details
Condition Malignant neoplasm of prostate, Prostatic disorder, Prostate Adenocarcinoma
Age 18years - 100years
Treatment External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy
Clinical Study IdentifierNCT04465500
SponsorUniversity of Virginia
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male, aged 18 or above
Histologic proven diagnosis of cancer of the prostate within one year of registration
Unfavorable-intermediate risk, high risk, or very high-risk prostate cancer as determined by the NCCN Guidelines Version 4.2019
History and physical exam (including digital rectal exam) completed within 60 days of registration
PSA value < 50 ng/mL
ECOG performance status 0 or 1

Exclusion Criteria

Evidence of bone metastases
Diagnosis of a prior invasive malignancy (except for non-melanoma skin cancer), unless the participant has been disease-free for at least 3 years
Patient has had previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Patient has had previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Patient has had prior radiotherapy, including brachytherapy, to the region of this study cancer that would result in overlap of radiation therapy fields
Patient has had previous or concurrent cytotoxic chemotherapy for prostate cancer (prior chemotherapy for different cancer is allowed)
Patient has MRI incompatible metallic implant(s) that cannot be removed
The patient has severe or active co-morbidities as defined by the following
Unstable angina and/or congestive heart failure requiring hospitalization within 6 months (180 days) of registration
Transmural myocardial infarction within 6 months (180 days) of registration
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Hepatic insufficiency resulting in clinical jaundice and/or coagulation effects or severe liver dysfunction
Acquired immune deficiency syndrome (AIDS) based upon current CDC definition. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be slightly immunosuppressive. Protocol-specific requirements may also exclude immuno-compromised patients
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
adenocarcinoma
prostate adenocarcinoma
androgens
pelvic mri
brachytherapy
digital rectal examination
external beam radiation therapy
digital rectal exam
antiandrogen therapy
adenocarcinoma of prostate
androgen suppression
prostate cancer

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.